Physician profile
Jean A Yared
NPI 1881871879
$37,924.52
in general payments reported to CMS, 2019-2025
31 companies · $5,563 in 2025
The $5,563 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,253 · 2020: $4,581 · 2021: $3,430 · 2022: $8,852 · 2023: $7,772 · 2024: $1,473 · 2025: $5,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,630 · Honoraria: $3,750 · Travel and Lodging: $2,777 · Food and Beverage: $2,576 · Education: $74.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,630.00 |
| Honoraria | $3,750.00 |
| Travel and Lodging | $2,777.33 |
| Food and Beverage | $2,576.39 |
| Education | $74.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $8,489.62 | 2022-2025 | |
| Incyte Corporation | $6,859.87 | 2023-2025 | Jakafi, Monjuvi, Niktimvo |
| Jazz Pharmaceuticals INC. | $5,761.04 | 2019-2025 | |
| Kite Pharma, INC. | $5,014.00 | 2019-2023 | Yescarta |
| Pierre Fabre Pharmaceuticals, INC. | $4,742.83 | 2025 | |
| Omeros Corporation | $3,300.00 | 2021 | |
| National Marrow Donor Program | $1,988.12 | 2022-2024 | |
| Amgen INC. | $286.56 | 2019-2022 | |
| Genetix Biotherapeutics INC | $221.50 | 2023-2025 | Lyfgenia |
| Daiichi Sankyo INC. | $140.36 | 2023-2025 | Enhertu, Vanflyta |
| Kadmon Pharmaceuticals LLC | $130.16 | 2021 | |
| Celgene Corporation | $129.87 | 2022 | |
| Janssen Biotech, INC. | $126.66 | 2023-2025 | Tecvayli, Rybrevant, Talvey |
| Genzyme Corporation | $124.15 | 2025 | |
| Biolinerx USA, INC. | $110.14 | 2024 | Aphexda |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $74.42 | 2023 | Abecma |
| Abbvie INC. | $66.50 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $56.96 | 2024-2025 | Calquence |
| Syndax Pharmaceuticals, INC. | $55.61 | 2025 | |
| Gilead Sciences, INC. | $55.59 | 2025 | Yescarta |
| Astellas Pharma US INC | $43.71 | 2019 | |
| Pfizer INC. | $39.96 | 2025 | |
| Gamida Cell INC. | $26.81 | 2025 | Omisirge |
| Takeda Pharmaceuticals U.S.A., INC. | $25.92 | 2024 | Alunbrig |
| Merck Sharp & Dohme LLC | $24.38 | 2024 | Welireg, Keytruda |
| Servier Pharmaceuticals LLC | $16.12 | 2025 | |
| Lilly USA, LLC | $13.66 | 2023 | Verzenio, Jaypirca |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Yared listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.